ALDH+ Cancer Precursor Cells in Drug Response Prediction

Mr. Ed Field, Chief Operating Officer at Aldagen, explains the principles behind ALDEFLUOR™-based detection of ALDH bright cells and discusses evidence demonstrating ALDH’s potential as a biomarker for cancer stem cell characterization and tumor prognosis.
Publish Date: June 25, 2015 Views: 0